Testicular Cancer Risk Comes from Inherited Genetic Faults
By LabMedica International staff writers Posted on 20 Sep 2015 |
Image: Histopathology of a testicular seminoma with classical histologic features including a prominent lymphoid stromal infiltrate and typical cytomorphology (Photo courtesy of Mattopaedia).
Testing for a range of genetic variants linked to testicular cancer could be effective in picking out patients who are at substantially increased risk, and therefore, potentially opening up ways of preventing the disease.
Almost half of the risk of developing testicular cancer comes from the DNA passed down from parents and genetic inheritance is much more important in testicular cancer than in most other cancer types, where genetics typically accounts for less than 20% of risk.
Scientists at The Institute of Cancer Research (ICR; London, UK) along with colleagues in Germany, Sweden, and the USA, used two independent approaches to analyze the risk of testicular germ cell tumors which easily the most common type of testicular cancer. They used statistical analysis to examine patterns of ancestral testicular cancer in family groups across 15.7 million people from the Swedish Population Registry cancer family database, including 9,324 cases of testicular cancer. They then looked in detail at the genetic code of 6,000 UK men from two previous testicular cancer studies, 986 of whom had been diagnosed with the disease.
The combined Genome-Wide Complex Trait Analysis revealed that 49% of all the possible factors contributing to testicular cancer risk are inherited. They found that the inherited risk comes from a large number of minor variations in DNA code, rather than one faulty gene with a broad effect. Although substantial inroads have been made over the last five years at the ICR into identifying mutations associated with risk of testicular cancer, the study also showed that these known mutations only account for 9.1% of the risk of developing the disease. Therefore the majority of the genetic variants that raise testicular cancer risk have yet to be identified. There was a higher hereditability for seminomas at 42.2% as compared for non-seminomas at 29.4%.
Clare Turnbull, PhD, a senior author of the study, said, “Our study has shown that testicular cancer is a strongly heritable disease. Around half of a man's risk of developing testicular cancer comes from the genes he inherits from his parents, with environmental and behavioral factors contributing to the other half. Our findings have important implications in that they show that if we can discover these genetic causes, screening of men with a family history of testicular cancer could help to diagnose those at greatest risk, and help them to manage that risk.” The study was published on September 9, 2015, in the journal Scientific Reports.
Related Links:
The Institute of Cancer Research
Almost half of the risk of developing testicular cancer comes from the DNA passed down from parents and genetic inheritance is much more important in testicular cancer than in most other cancer types, where genetics typically accounts for less than 20% of risk.
Scientists at The Institute of Cancer Research (ICR; London, UK) along with colleagues in Germany, Sweden, and the USA, used two independent approaches to analyze the risk of testicular germ cell tumors which easily the most common type of testicular cancer. They used statistical analysis to examine patterns of ancestral testicular cancer in family groups across 15.7 million people from the Swedish Population Registry cancer family database, including 9,324 cases of testicular cancer. They then looked in detail at the genetic code of 6,000 UK men from two previous testicular cancer studies, 986 of whom had been diagnosed with the disease.
The combined Genome-Wide Complex Trait Analysis revealed that 49% of all the possible factors contributing to testicular cancer risk are inherited. They found that the inherited risk comes from a large number of minor variations in DNA code, rather than one faulty gene with a broad effect. Although substantial inroads have been made over the last five years at the ICR into identifying mutations associated with risk of testicular cancer, the study also showed that these known mutations only account for 9.1% of the risk of developing the disease. Therefore the majority of the genetic variants that raise testicular cancer risk have yet to be identified. There was a higher hereditability for seminomas at 42.2% as compared for non-seminomas at 29.4%.
Clare Turnbull, PhD, a senior author of the study, said, “Our study has shown that testicular cancer is a strongly heritable disease. Around half of a man's risk of developing testicular cancer comes from the genes he inherits from his parents, with environmental and behavioral factors contributing to the other half. Our findings have important implications in that they show that if we can discover these genetic causes, screening of men with a family history of testicular cancer could help to diagnose those at greatest risk, and help them to manage that risk.” The study was published on September 9, 2015, in the journal Scientific Reports.
Related Links:
The Institute of Cancer Research
Latest Molecular Diagnostics News
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer